benserazide
Small molecule targets DDC via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04432623 | Oct 2020 → Feb 2026 overdue | beta-thalassemia intermedia, sickle cell disease | Phoenicia BioScience | Enrolling by invitation | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00144209 | Feb 2003 → Feb 2005 | restless legs syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01327261 | Aug → Oct 2009 | — | University of Buenos Aires | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT00941265 | Feb 2007 → Aug 2009 | aphasia | University Hospital, Geneva | Completed | No outcome recorded |
| Comparator or background therapy14 trials | ||||||
| Phase 0 | NCT03333369 Comparator | May 2014 → Aug 2015 | schizotypal personality disorder | University of Zurich | Completed | No outcome recorded |
| Phase 1 | NCT02169895 Background | Sep → Nov 2008 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03097211 Background | Jul → Oct 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03094156 Background | Apr → Jul 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02778594 Background | Sep → Nov 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03091543 Background | May → Jul 2004 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02763852 Background | Apr → Jul 2001 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 2 | NCT02680977 Comparator | Feb → May 2016 | Parkinson disease | ASST Gaetano Pini-CTO | Completed | No outcome recorded |
| Phase 2 | NCT03103399 Background | Sep 2006 → Sep 2007 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01568073 Background | Mar 2011 → Nov 2013 | Parkinson disease | Bial - Portela C S.A. | Completed | Met primary |
| Phase 3 | NCT01227655 Background | Mar 2011 → Jul 2012 | Parkinson disease | Bial - Portela C S.A. | Completed | Met primary |
| Phase 4 | NCT04990284 Background | Nov 2021 → Apr 2023 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 4 | NCT00812760 Background | Oct 2001 → Oct 2003 | retinal disorder | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT06365515 Background | May 2024 → Dec 2025 | menstrual disorder | University Hospital Tuebingen | Unknown | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benserazide | “1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.” NCT03091543 ↗17“To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019).” NCT06365515 ↗ “Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]” NCT03094156 ↗ “Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.” NCT02763852 ↗ “a single-dose of immediate-release levodopa/benserazide 100/25 mg (Prolopa® 100-25)” NCT02169895 ↗ “L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration” NCT04990284 ↗ “Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide)” NCT03103399 ↗ “Levodopa/benserazide immediate release tablets 200mg/50mg.” NCT03097211 ↗ “1 tablet of 200 mg levodopa plus 50 mg benserazide” NCT00812760 ↗ “Levodopa plus Benserazide” NCT02680977 ↗ |
| Known as | Benserazida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Known as | Benserazide (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Known as | Benserazide component of madopar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Known as | Benserazide component of prolopa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Known as | Benserazide hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Known as | BENSERAZIDE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Known as | Benserazide Only Product | “Drug: Benserazide Only Product” NCT04432623 ↗ |
| Known as | NSC-755907 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Known as | RO 4-4602 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Known as | Serazide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096979 ↗ |
| Action | Inhibit | “The study drug acts by suppressing 4 repressors of the fetal globin gene promoter in progenitor cells.” NCT04432623 ↗1“DOPA decarboxylase inhibitor” CHEMBL1096979 ↗ |
| Modality | Small molecule | — CHEMBL1096979 ↗ |
| Route | Oral | “Every period with concomitant single oral administration of Prolopa® 100-25” NCT02169895 ↗ |
| Target | DDC | “DOPA decarboxylase inhibitor” CHEMBL1096979 ↗ |